Key result
Adoption of the 2017 ACC/AHA hypertension guidelines would relatively increase the prevalence of hypertension by 26.8% in the US and 45.1% in China compared to JNC-8 guidelines.
Why the study?
What is the impact of the 2017 ACC/AHA hypertension guidelines on the prevalence of hypertension and treatment eligibility in the US and China compared to previous guidelines?
Population
Adults 45 to 75 years of age from the US (NHANES 2013-2016) and China (CHARLS 2011-2012)
Comparison
Application of 2017 ACC/AHA hypertension… vs Application of current/previous hypertension…
Design
Cross-sectional
Authors
Loading...
Will markedly expand US hypertensive population and treatment eligibility; supports updated policy planning but requires prospective validation before broad implementation.
Cross-Sectional
What is the impact of the 2017 ACC/AHA hypertension guidelines on the prevalence of hypertension and treatment eligibility in the US and China compared to previous guidelines?
Effect estimate: 26.8% relative increase in the US
Absolute Event Rate: 63% vs 49.7%
p-value: p=<0.01
The 2017 ACC/AHA hypertension guidelines significantly expand the population labeled with hypertension and those eligible for treatment initiation and intensification in both the US and China.
Khera et al. (2017) conducted a cross-sectional in Hypertension. 2017 ACC/AHA hypertension guidelines vs. JNC-8 guidelines was evaluated on Prevalence of hypertension (26.8% relative increase in the US, p=<0.01). Adoption of the 2017 ACC/AHA hypertension guidelines would relatively increase the prevalence of hypertension by 26.8% in the US and 45.1% in China compared to JNC-8 guidelines.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: